Powered by: Motilal Oswal
6/08/2021 11:44:42 AM | Source: ICICI Direct
Buy Rallis India Ltd For Target Rs. 400 - ICICI Direct
News By Tags | #872 #1660 #3961 #1302 #178
Buy Rallis India Ltd For Target Rs. 400 - ICICI Direct

Ongoing capex portends well for future performance

About the stock:

Rallis India is a leading agrochemical company with a presence across the agri input value chain and a strong and healthy pipeline of sustainable products.

* The company has a diversified portfolio, supported by a strong channel network of more than 6,700 dealers and 79,000 retailers

* In terms of revenue contribution, domestic crop care constitutes 54% of the overall revenue followed by international crop care of 30% and rest from seeds business

 

Q1FY22 Results:

Revenue was ahead of our estimates while PAT came in lower than expected owing to lower gross margins and higher operating cost.

* Reported revenue growth of 11.7% YoY to | 740.5 crore, led by domestic crop care business (up 32% YoY)

* Gross margins declined 90 bps YoY to ~38.8% while EBITDA margin contracted 300 bps YoY to 16.4%, due to higher operating cost such as employee & other expenses

* EBITDA was down 5.3% YoY to | 121.5 crore  PAT fell 10% YoY to | 82.3 crore owing to lower than expected operational performance

 

What should investors do?

The stock appreciated at 95% CAGR in last two years

* We retain BUY rating on the back of better growth outlook from both domestic and international crop care business

Target Price and Valuation: We value Rallis India at 25x P/E FY23E EPS to arrive at a revised target price of | 400 per share (earlier | 350 per share)

 

Key triggers for future price performance:

* Lower pricing pressure for key molecules in the international market along with better volume growth visibility

* Backward integration of few technicals can likely translate into improvement in gross margins

* Increase in custom synthesis/CRAMS business revenue

 

Alternate Stock Idea:

Apart from Rallis India, in our chemical coverage we also like Neogen Chemical

* Trigger for Neogen Chemical’s future revenue growth would be increasing CRAMS opportunity

* BUY with a target price of | 1085

 

To Read Complete Report & Disclaimer Click Here

 

https://secure.icicidirect.com/Content/StaticData/Disclaimer.html

 

Above views are of the author and not of the website kindly read disclaimer

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here